metformin
Commercial- Indications
- Type 2 diabetes
Company intelligence / Profile preview
ALZA was a pioneer in drug delivery technologies and brought over twenty prescription pharmaceutical products to market. Its platforms enabled controlled-release and transdermal therapies that improved efficacy and patient compliance. Many of its products became blockbusters through partnerships or licensing to major pharma companies. The company was acquired by Johnson & Johnson in May 2001 for $10.5 billion.[1][3]
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ALZA Corporation.